Venus Medtech Revenue and Competitors
Estimated Revenue & Valuation
- Venus Medtech's estimated annual revenue is currently $7.2M per year.
- Venus Medtech's estimated revenue per employee is $126,000
Employee Data
- Venus Medtech has 57 Employees.
- Venus Medtech grew their employee count by 39% last year.
Venus Medtech's People
| Name | Title | Email/Phone |
|---|
Venus Medtech Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $14.1M | 101 | 5% | N/A | N/A |
#2 | $1.6M | 19 | -71% | N/A | N/A |
#3 | $212.8M | 1063 | 5% | $65M | N/A |
#4 | $6.8M | 54 | 8% | N/A | N/A |
#5 | $12.9M | 92 | 2% | $23.1M | N/A |
#6 | $1M | 12 | N/A | N/A | N/A |
#7 | $106.5M | 599 | -17% | $2.3M | N/A |
#8 | $35.6M | 231 | 6% | N/A | N/A |
#9 | $38.3M | 249 | 5% | N/A | N/A |
#10 | $45M | 299 | -4% | $102.6M | N/A |
What Is Venus Medtech?
Venus Medtech (Hangzhou) Inc. is a leading transcatheter heart valve medical device player in China in terms of implantation volume in 2018. The Company's self-developed product, VenusA-Valve, is the first transcather aortic heart valve replacement (“TAVRâ€) product approved by the National Medical Products Administration ("NMPA") and commercialized in China.
keywords:N/A
N/A
Total Funding
57
Number of Employees
$7.2M
Revenue (est)
39%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Venus Medtech News
These patients require intervention with Percutaneous pulmonary valve replacement. In 2011, Venus Medtech invited international doctors to...
As at June 2021, Venus Medtech (Hangzhou) had cash of CN¥3.6b and no debt. Looking at the last year, the company burnt through CN¥452m.
Venus Medtech boasts a best-in-class innovative cardiovascular device marketing team, which has by now expanded to 220 members. In 2021, the...
Other Companies in æå·ž
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1090M | 60 | -37% | N/A |
#2 | N/A | 70 | -25% | N/A |
#3 | $29M | 182 | -13% | N/A |
#4 | $29.7M | 186 | 2% | N/A |